 |
Behind
the Headlines - Vaccine 'could stop diabetes' |
| |
Although the study described above contributes
to the evidence suggesting that enterovirus could be one of these
triggering viruses, its results are not conclusive. More research
will be needed before it becomes clear whether a vaccine targeting
enterovirus can tackle type 1 diabetes (Behind the Headlines, NHSChoices) |
| |
|
|
Napping
increases risk of diabetes |
| |
Taking regular lunchtime siestas could increase
the risk of developing Type 2 diabetes, according to the findings
of a research study being presented this week at Diabetes UK’s Annual Professional Conference in Glasgow (Diabetes UK) |
| |
|
|
Feasibility
of using videoconferencing to provide diabetes education: a pilot
study |
| |
The results suggest that providing nutritional
therapy via videoconferencing may be useful in assisting patients
to manage their conditions (Journal of Telemedicine and Telecare) |
| |
|
|
The
inhibitory association of recent type 2 diabetes risk loci on
insulin secretion is modulated by insulin sensitivity |
| |
The negative effects of the risk alleles on ß-cell
function appear additive in subjects with low insulin sensitivity,
but not in subjects with high insulin sensitivity. Effective compensatory
mechanisms may exist in subjects with high insulin sensitivity
that limit these genes' impact (Journal of Clinical Endocrinology & Metabolism) |
| |
|
|
MannKind
Biopharmaceuticalsto Buy Pfizer Inc. (PFE)'s Insulin Plant in
Germany for $33 Million |
| |
MannKind Corporation announced that it has entered
into agreements with Pfizer Inc. to purchase Pfizer's insulin facility
at Industriepark Hoechst, Frankfurt am Main, Germany and assets
related to the production of bulk insulin, including the relevant
real property rights, the production equipment, a quantity of bulk
insulin and a license to manufacture bulk insulin for use in pulmonary
delivery (BioSpace) |
| |
|
|
Surface
Logix Raises $20 Million in Financing and Starts Phase 2b Clinical
Trial of SLx-4090 in Dyslipidemia and Diabetes |
| |
SLx-4090 has potential not only in dyslipidemia
but also in obesity and diabetes as a result of the compound's
ability to restrict energy absorption by reducing the uptake of
triglycerides (BioSpace) |
| |
|
